About P4 Medicine Institute

As an innovation consortium, the mission of the P4 Medicine Institute is to lead the emergence and adoption of healthcare of the future which will be predictive, preventive, personalized, and participatory.

The P4 Medicine Institute will revolutionize healthcare from a reactive state to one that delivers care of higher quality, increased satisfaction, and lower cost by applying systems biology and systems theory to medicine and care delivery. This will result in healthcare that predicts and prevents illness, focuses on health and wellness, and considers the consumer as the central figure in care.

P4MI's strategic initiatives include:

  • Establishing a consortium of innovative strategic partners who share our vision of P4 Medicine.
  • Demonstrating a new vision of healthcare based upon systems biology-driven insights by developing the technical and societal infrastructure needed to bring P4 Medicine to consumers.
  • Developing a new delivery model that places the consumer at the center of care, and engaging payers, providers, and industry in participatory medicine.
  • Advocating for policies at the national and global level that accelerate discovery, lower costs, improve health quality, and address the societal and legal implications of P4 Medicine.
 

The P4MI Team

Leroy Hood MD, PhD

 

Dr. Leroy Hood's research has focused on fundamental biology (immunity, evolution, genomics) and on bringing engineering to biology through the development of five instruments; the DNA and protein sequencers and synthesizers and the ink-jet oligonucleotide synthesizer (making DNA arrays) for deciphering the various types of biological information (DNA, RNA, proteins and systems). In particular, the DNA sequencer has revolutionized genomics by allowing the rapid automated sequencing of DNA, which played a crucial role in contributing to the successful mapping of the human genome during the 1990s and early 2000s. These instruments constitute the technological foundation for modern molecular biology and genomics. He has applied these technologies to diverse fields including immunology, neurobiology, cancer biology, molecular evolution and systems medicine.

Early in his career, Dr. Hood applied these technologies to the study of molecular immunology (and discovered many of the fundamental mechanisms for antibody diversity) and neurobiology (he cured the first neurological disease by gene transfer in mice).

Dr. Hood is now pioneering the idea that the systems approach to disease, the emerging technologies, and powerful new computational and mathematical tools will move medicine from its current reactive mode to a predictive, preventive, personalized and participatory mode (P4 medicine) over the next 5-20 years.

Dr. Hood has received 17 honorary degrees from Institutions such as Johns Hopkins, Yale, UCLA, and Whitman College. He has published more than 680 peer-reviewed papers, received 15 patents, and has co-authored textbooks in biochemistry, immunology, molecular biology, and genetics, and is just finishing a textbook on systems biology. In addition, he coauthored with Dan Keveles a popular book on the human genome project—The Code of Codes.

Dr. Hood is one of only 7 (of more than 6000 members) scientists elected to all three academies (NAS, NAE and IOM). Dr. Hood has also played a role in founding more than 14 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. He is currently pioneering systems medicine and the systems approach to disease and has recently cofounded the company Integrated Diagnostics—that hopefully will become a platform company for P4 medicine.

Frederick Lee MD, MPH

Executive Director, P4 Medicine Institute

Fred Lee is the Executive Director of the P4 Medicine Institute. He brings a broad range of perspectives to this task, having spent time as a provider, as a healthcare system executive, and as an industry executive. From the industry perspective, Fred led product strategy efforts for McKesson Corporation in its Provider Technologies division, focusing on developing clinical informatics solutions to support genomic & molecular medicine. He has also held leadership roles in General Electric Healthcare, leading product strategy for GE Healthcare Integrated Information Technologies in the United Kingdom while working on the UK's National Health Service Connecting for Health program.

Fred has held executive leadership roles in health systems in the New York / Long Island area, as a Chief Operating Officer and as a Chief Medical Information Officer of a large ambulatory care network in New York.

Fred's clinical background is in general surgery and preventive medicine. He received a BS from the Massachusetts Institute of Technology in Life Sciences, an MD and residency training from the Stony Brook University School of Medicine, and an MPH from Mailman School of Public Health at Columbia University.